Saturday, October 31, 2026

USD/JPY: Plenty Of Scope For Yen Bulls To Be Disappointed This Year – Rabobank: (USDJPY) Is 1% Up In The Last 10 Sessions

Via News Just in

January 9, 2024

USD/JPY: Plenty Of Scope For Yen Bulls To Be Disappointed This Year – Rabobank: (USDJPY) Is 1% Up In The Last 10 Sessions

(VIANEWS) - USD/JPY traded at the highest level since mid-December on Friday. Economists at Rabobank analyze the pair's outlook.

FXStreet reported that we adhere to the view that the BoJ is unlikely to consider a rate hike before April, allowing for consideration of the spring wage deals and the latest fiscal stimulus package.

The overriding theme of BoJ policy is likely to be caution. This suggests plenty of scope for JPY bulls to be disappointed this year.

USD/JPY (USDJPY) has been up by 1.27% for the last 10 sessions. At 18:08 EST on Monday, 8 January, USD/JPY (USDJPY) is $144.15.

Usd/jpy analysis: eyes on central bank policies - 08 January 2024

The improvement in US job numbers stronger than all expectations helped the USD/JPY bulls rush towards the 145.98 resistance level. , The USD/JPY pair is still trading inside an upward channel that formed recently.

USD/JPY's yearly highs and lows, it's 13.275% up from its 52-week low and 5.106% down from its 52-week high.

Volatility

USD/JPY's last week, last month's, and last quarter's current intraday variation average was 0.67%, 0.02%, and 0.46%, respectively.

USD/JPY's highest amplitude of average volatility was 0.67% (last week), 0.53% (last month), and 0.46% (last quarter), respectively.

Forex Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, USD/JPY's Forex is considered to be oversold (<=20).

More news about USD/JPY (USDJPY).

Via News Just in

Breaking news and real-time updates on financial markets, business developments, and economic events from Via News.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Catalyst Cluster: Ivonescimab's PDUFA Date and Small-Cap Biotech Delistings
ESMO 2026 (Oct 22-24) concentrates a wave of oncology readouts. Summit's ivonescimab (10 presentations, positive HARMONi-GI1 OS, new EA2251 Phase II/III with ECOG-ACRIN) leads, ahead of its FDA PDUFA date of 2026-11-14, and Daiichi Sankyo's DXd ADC platform (REJOICE-Ovarian, DESTINY-Lung04, TUXEDO-3) follows. At the other end of the capital-markets spectrum, micro-cap Spago Nanomedical is moving to delist from Nasdaq First North (board resolution Oct 22, EGM Nov 19, application Jan 2027). Pivotal data and regulatory milestones are rewarding well-funded late-stage players, while cash-constrained early-stage developers are exiting public markets.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,525 source documents archived
Query this data → isubstrate.com